Blog

RSS Feed
Posted by Michael Wonder on 28 Jul 2016

EMA publishes EPAR for Zepatier (grazoprevir with elbasvir)

28 July 2016 - The EMA has published an EPAR for Merck's Zepatier. ...

Read more →
Posted by Michael Wonder on 28 Jul 2016

EMA publishes EPAR for Epclusa (sofosbuvir with velpatasvir)

28 July 2016 - The EMA has published an EPAR for Gilead's Epclusa. ...

Read more →
Posted by Michael Wonder on 08 Jul 2016

European Commission grants marketing authorization for Gilead’s Epclusa (sofosbuvir/velpatasvir) for the treatment of all genotypes of chronic hepatitis C

8 July 2016 - Epclusa is the first and only all-oral, single tablet regimen for all genotypes (1-6) of chronic hepatitis ...

Read more →
Posted by Michael Wonder on 27 May 2016

Highlights from the CHMP 23-26 May 2016 meeting

27 May 2016 - Six medicines, including two combination therapies for chronic hepatitis C, recommended for approval. ...

Read more →
Posted by Michael Wonder on 27 May 2016

Two new combination therapies against chronic hepatitis C

27 May 2016 - Direct-acting antivirals Epclusa and Zepatier recommended for approval. ...

Read more →
Posted by Michael Wonder on 23 May 2016

Agenda for the May 2016 CHMP meeting

23 May 2016 - The agenda for the 23-26 May 2016 CHMP meeting is now available. ...

Read more →